We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .
Transforming growth factor-beta1 in mothers' colostrum and immune responses to cows' milk proteins in infants with cows' milk allergy.
BACKGROUND Breast milk contains immune factors that compensate for the underdeveloped defenses of the gut of the newborn infant . OBJECTIVE We sought to study the importance of these factors in the immune responses of infants with cows ' milk allergy ( CMA ) to the proteins in cows ' milk ( CM ) . METHODS We prospect ively followed the development of CMA in 6209 healthy infants and collected sample s of colostrum from mothers .  Sample s from mothers of infants with CMA and from control subjects were analyzed for immunoglobulins , CM-specific antibodies , and cytokines . In infants with CMA , correlations between the concentration of transforming growth factor (TGF)-beta1 in colostrum and the extent of the immune response to CM proteins were studied . RESULTS The concentration of TGF-beta1 in colostrum sample s from mothers of infants with IgE-mediated CMA ( n = 65 ) was lower ( mean , 589 pg/mL ; 95 % confidence interval [ CI ] , 413 - 840 ) than from mothers of infants with non-IgE-mediated CMA ( n = 37 ; mean , 1162 pg/mL ; 95 % CI , 881 - 1531 ; t = 2.57 , P = .012 ) . In 126 control subjects the mean concentration was 807 pg/mL ( 95 % CI , 677 - 963 ) . In the infants with CMA ( n = 96 - 100 ) , the concentration of TGF-beta1 in colostrum was positively correlated with IgA antibodies to beta-lactoglobulin and IgG antibodies to alpha-casein and whole formula and negatively with the diameter of a skin prick test response to CM and lymphocyte stimulation indices to alpha-casein and beta-lactoglobulin . CONCLUSIONS In an infant prone to having CMA , the TGF-beta1 content of mother 's colostrum may promote IgG-IgA antibody production and inhibit IgE- and cell-mediated reactions to CM
We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .